Medrx Co. Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Full Year Ended December 31, 2016; Provides Earnings Guidance for the Six Months Ending June 2017 and Year Ending December 31, 2017
February 09, 2017
Share
Medrx Co. Ltd. reported consolidated and non-consolidated earnings results for the full year ended December 31, 2016. For the year, on consolidated basis, the company reported consolidated net sales of JPY 22 million, operating loss of JPY 1,342 million, ordinary loss of JPY 1,301 million, net loss of JPY 1,259 million or JPY 155.48 per diluted share, compared to net sales of JPY 37 million, operating loss of JPY 999 million, ordinary loss of JPY 990 million, net loss of JPY 878 million or JPY 131.21 per diluted share, a year ago. Cash flows from operating activities were JPY 1,215 million against JPY 789 million a year ago.
For the year, on non-consolidated basis, the company reported consolidated net sales of JPY 22 million, operating loss of JPY 1,340 million, ordinary loss of JPY 1,324 million, net loss of JPY 1,575 million or JPY 194.60 per diluted share, compared to net sales of JPY 37 million, operating loss of JPY 988 million, ordinary loss of JPY 971 million, net loss of JPY 858 million or JPY 128.30 per diluted share, a year ago.
For the six months ending June 2017, the company expects consolidated net sales of JPY 17 million, operating loss of JPY 514 million, ordinary loss of JPY 499 million, and net loss of JPY 459 million or JPY 53.92 per share.
For the year ending December 31, 2017, the company expects consolidated net sales of JPY 26 million, operating loss of JPY 1,421 million, ordinary loss of JPY 1,404 million, and net loss of JPY 1,366 million or JPY 160.49 per share.
Medrx Co., Ltd. is a Japan-based Company principally engaged in the research and development of pharmaceutical products. The Company produces new medicines based on percutaneous absorption formulation technology. The Company has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.
Medrx Co. Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Full Year Ended December 31, 2016; Provides Earnings Guidance for the Six Months Ending June 2017 and Year Ending December 31, 2017